Artificial Intelligence Guided Production of Cells and Organs from Pluripotent Stem Cells
Disclosed are systems, means and compositions of matter utilizing artificial intelligence to create unique cells and/or organs from pluripotent stem cells. In one embodiment an artificial intelligence/machine learning approach is utilized to overview and categorize molecular and cellular data regarding normal embryonic development and associated pathways. Through acquiring this information, said artificial intelligence/machine learning system develops a graded list of morphogens/differentiating agents and/or conditions that are utilized to replicate the process of cell/tissue/organ formation artificially. In one embodiment the invention teaches generation of artificial pancreatic organoids through growth factors predicted by said artificial intelligence/machine learning systems. In other embodiments embryogenesis is recapitulated in adult tissue using predicted morphogens and/or extracellular matrix treatments.
1 . A method for identifying agents capable of inducing specific differentiation of pluripotent stem cells into a particular tissue through the utilization of a computing system, said comprising: a) obtaining information regarding cellular and molecular characteristics of an embryonic developing tissue; b) analyzing one or more molecular and/or cellular features of the tissue during stages of differentiation, wherein analyzing the one or more features includes using an artificial intelligence architecture that includes a separable convolutional neural network; and based at least in part on the analysis of the one or more features; and c) obtaining predictive data in the form of associated proteins, extracellular matrix, and nucleic acids that are associated with the process of differentiation.
2 . The method of claim 1 , which is enabled/designed to create a score for each of the one or more methodologies and/or molecular pathways associated with cellular differentiation, wherein the score reflects the likelihood that an said pathway and/or methodology contains a the necessary information and/or detail to reproducibly generate differentiation of said pluripotent stem cells into a desired tissue and/or organ.
3 . The method of claim 1 , further comprising indicating whether the one or more molecular pathways and/or methodologies have synergy and/or antagonism.
4 . The method of claim 1 , wherein the one or more molecular pathways associated with differentiation to a specific tissue comprises a dataset of differentiating factors which are corresponding to a biological sample taken from a single subject.
5 . The method of claim 1 , wherein said pluripotent stem cell is an inducible pluripotent stem cell.
6 . The method of claim 5 , wherein said inducible pluripotent stem cell is generated by a mechanical stress associated means.
7 . The method of claim 6 , wherein said thymus derived cell expresses the marker CD28.
8 . The method of claim 6 , wherein said thymus derived cell expresses the marker ICOS.
9 . The method of claim 6 , wherein said thymus derived cell has been treated with a histone deacetylase inhibitor.
10 . The method of claim 9 , wherein said histone deactylase inhibitor is anexinostat.
11 . The method of claim 9 , wherein said histone deactylase inhibitor is bg45.
12 . The method of claim 5 , wherein said cell to be converted to a pluripotent stem cell by said mechanical stress associated means is plated in a droplet that partially or fully surrounds said somatic cell.
13 . The method of claim 12 , wherein forming the droplet includes pressurized flow through an orifice without heat but with increased atmospheric pressure compared to baseline conditions.
14 . The method of claim 13 , said increased atmospheric pressure is sufficient to induce activation of janus activated kinase.
15 . The method of claim 12 , wherein forming the droplet includes using an ultrasonic transducer.
16 . The method of claim 12 , further comprising printing the pluripotent stem cell on a substrate and incubating the pluripotent stem cell.
17 . The method of claim 16 , wherein said decellularized matrix is obtained from omental tissue.
18 . The method of claim 16 , wherein said decellularized matrix is obtained from intestinal mucosal tissue.
19 . The method of claim 16 , wherein said decellularized matrix is obtained from placental tissue.
20 . The method of claim 19 , wherein said placental matrix is treated with a Nobel gas prior to utilization.